Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy ( FSHD) did not achieve functional secondary endpoints in the Phase 2 trial. Although ACE-083 demonstrated […]
[…] review by our Scientific Advisory Board. They include deep dives into how the genetics of FSHD affects the early development of muscle cells and into the lingering and all-important mystery […]
Driving Breakthroughs for FSHD Treatments The FSHD Therapeutic Accelerator, spearheaded by the FSHD Society, is a comprehensive initiative designed to fast-track the development of effective treatments for FSHD. This groundbreaking […]
Living with FSHD requires a team approach. In order to get the care you need, you may need to see a few different types of doctors and providers. Read more […]
We have been notified that researchers at the UC Davis Medical School are seeking FSHD patients to volunteer for a study. Read here about why participating in research is so […]
